AXIM BiotechnologiesAXIM +9.09% EV-to-EBITDA is 20.58 as of Jul. 09, 2026. Among 392 Biotechnology companies, AXIM Biotechnologies ranks worse than 63.01% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AXIM Biotechnologies's enterprise value is $8.97 Mil.
AXIM Biotechnologies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was $0.44 Mil. Therefore, AXIM Biotechnologies's EV-to-EBITDA for today is 20.58.
The historical rank and industry rank for AXIM Biotechnologies's EV-to-EBITDA or its related term are showing as below:
AXIM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 20.58
Current: 20.58
During the past 13 years, the highest EV-to-EBITDA of AXIM Biotechnologies was 20.58. The lowest was 0.00. And the median was 0.00.
AXIM's EV-to-EBITDA is ranked worse than 63.01% of 392
companies
in the Biotechnology industry
Industry Median: 12.965
vs AXIM: 20.58
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AXIM Biotechnologies's PE Ratio (TTM) for today is calculated as:
AXIM Biotechnologies's share price for today is $0.0042.
AXIM Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for AXIM Biotechnologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AXIM Biotechnologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AXIM Biotechnologies EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AXIM Biotechnologies's EV-to-EBITDA falls into.
AXIM Biotechnologies's current Enterprise Value is $8.97 Mil.
AXIM Biotechnologies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM Biotechnologies (AXIM) has a EV-to-EBITDA of 20.58 as of Jul. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AXIM Biotechnologies. According to the industry distribution chart, AXIM Biotechnologies ranks #247 out of 392 companies in the Biotechnology industry, placing it in the top 63%.
Is AXIM Biotechnologies' EV-to-EBITDA too high?
AXIM Biotechnologies' current EV-to-EBITDA is 20.58. The Biotechnology industry median EV-to-EBITDA is 12.97. AXIM Biotechnologies' value of 20.58 is 58.7% above this industry median. Based on the distribution chart, AXIM Biotechnologies ranks #247 out of 392 companies in the Biotechnology industry, which is below the industry midpoint.
How does AXIM Biotechnologies' EV-to-EBITDA compare to ZVSA and HEPA?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #247 out of 392 companies for EV-to-EBITDA. This places AXIM Biotechnologies in the lower half of its industry. The industry median EV-to-EBITDA is 12.97. AXIM Biotechnologies' value of 20.58 is 58.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.97, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AXIM Biotechnologies's current EV-to-EBITDA of 20.58 is 58.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AXIM Biotechnologies. For the Biotechnology industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AXIM Biotechnologies's current EV-to-EBITDA is 20.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current EV-to-EBITDA of 20.58. The current EV-to-EBITDA is 20.58 and 58.7% above the Biotechnology industry median of 12.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current EV-to-EBITDA is 20.58 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXIM has been successfully added to your 